small molecule glp-1 agonist Drug Hunter's 2023 Patent Review of GLP-1R Agonists | Drug Hunter posted on the topic Orforglipron, an Oral Small-Molecule GLP-1
Description
Two clinical trials were done on semaglutide and Alzheimers, and they did not show any benefits, Low Wang said
Contraindicated in individuals with a personal or family history of medullary thyroid carcinoma (MTC) or MEN 2
For all-cause mortality and RFS in patients with obesity, the 5-year survival probability was 97.4% and 96% with GLP-1 RA use, and 93.2% and 91.3% with non-use, respectively
Some have stockpiled compounded versions before losing access
Robert Kushner: Regarding body weight, that's very similar
[PubMed] [Google Scholar] 350.Vrang N., Phifer C.B., Corkern M.M., Berthoud H.R
